![](https://news.europawire.eu/wp-content/uploads/2018/12/Sandoz-new-144x144.jpg)
(IN BRIEF) Sandoz, a global leader in generic and biosimilar medicines, has signed a Memorandum of Understanding to build a new biologics production plant in Lendava, Slovenia, in a move expected to be worth at least USD 400 million. The … Read the full press release